Results 21 to 30 of about 4,214,171 (152)

Developmental trends in targeted radionuclide therapy : Biological aspects

, 2008
Targeted radionuclide therapy of hematopoietic malignancies in the clinical setting has been achieved and similar successes with solid tumors and cells disseminated from them are likely within reach.
Carlsson, Jörgen,
core   +8 more sources

Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

Pharmaceutics, 2022
Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents.
Caroline P. Kerr, Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert, Zachary S. Morris   +5 more
doaj   +1 more source

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy

Pharmaceutics, 2023
The precise delivery of cytotoxic radiation to cancer cells through the combination of a specific targeting vector with a radionuclide for targeted radionuclide therapy (TRT) has proven valuable for cancer care.
Cyprine Neba Funeh, Jessica Bridoux, Thomas Ertveldt, Timo W. M. De Groof, Dora Mugoli Chigoho, Parinaz Asiabi, Peter Covens, Matthias D’Huyvetter, Nick Devoogdt   +8 more
doaj   +1 more source

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review

Pharmaceutics, 2023
The actinium-225 (225Ac) radioisotope exhibits highly attractive nuclear properties for application in radionuclide therapy. However, the 225Ac radionuclide presents multiple daughter nuclides in its decay chain, which can escape the targeted site ...
Sipho Mdanda, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge, Jan Rijn Zeevaart   +4 more
doaj   +1 more source

Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers

Royal Society Open Science, 2023
Targeted radionuclide therapy (TRT) is a promising strategy to treat different types of cancer. TRT relies on a targeting vector used to deliver a therapeutic radionuclide specifically to the tumour site.
Erika Murce, Erik de Blois, Sophie van den Berg, Marion de Jong, Yann Seimbille   +4 more
doaj   +1 more source

Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.

PLoS ONE, 2021
RationaleMurine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present studies on the safety
Kara Magee, Ian R Marsh, Michelle M Turek, Joseph Grudzinski, Eduardo Aluicio-Sarduy, Jonathan W Engle, Ilene D Kurzman, Cindy L Zuleger, Elizabeth A Oseid, Christine Jaskowiak, Mark R Albertini, Karla Esbona, Bryan Bednarz, Paul M Sondel, Jamey P Weichert, Zachary S Morris, Reinier Hernandez, David M Vail   +17 more
doaj   +1 more source

PD16-11 COMPARISON OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED RADIONUCLIDE THERAPY (TRT) WITH LUTETIUM-177 ( ¹⁷⁷ LU) VIA ANTIBODY J591 VS SMALL MOLECULE LIGAND PSMA-617 [PDF]

Journal of Urology, 2020
INTRODUCTION AND OBJECTIVE:PSMA is established for TRT with either monoclonal antibodies (mAb) or small molecule ligands.
Muhammad Junaid Niaz*, Myrto Skafida, Joseph Osborne, David Nanus, Anna Molina, Charlene Thomas, Shankar Vallabhajosula, Paul Christos, Neil Bander, Scott Tagawa   +9 more
openaire   +1 more source

Perspective for use of the radionuclide drugs in the treatment of malignant tumors in Russiaw

Качественная клиническая практика, 2018
This article reviews perspective of the targeted radionuclide therapy (TRT) as one of the rapidly growing fields of nuclear medicine. The characteristics, features of action, advantages and disadvantages of the most used α- and β-emitters (223Ra, 213Bi ...
S. K. Zyryanov, K. E. Zatolochina
doaj   +1 more source

Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

Journal for ImmunoTherapy of Cancer, 2022
Background Systemic radiation treatments that preferentially irradiate cancer cells over normal tissue, known as targeted radionuclide therapy (TRT), have shown significant potential for treating metastatic prostate cancer.
Douglas G McNeel, Hemanth K Potluri, Ohyun Kwon, Joseph Grudzinski, Christopher Massey, Reinier Hernandez, Carolina A Ferreira, Eduardo Aluicio-Sarduy, Jonathan W Engle, Ian R Marsh, Bryan P Bednarz, Jamey P Weichert   +11 more
doaj   +1 more source

Bridging the Gaps in Fibroblast Activation Protein Targeted Radionuclide Therapy: A Translational Perspective [PDF]

European Journal of Nuclear Medicine and Molecular Imaging
Bart Cornelissen, Andor W J M Glaudemans, Chunhui Wu   +2 more
exaly   +2 more sources